An actigraphy-based nap detection algorithm reliably identifies nap-based phenotypes that differentiate individuals with narcolepsy type 1 from healthy controls, and demonstrates that an orexin receptor 2-selective agonist reduces napping to normative levels.
The study developed and validated an actigraphy-based nap detection algorithm with high specificity (93.2%) and accuracy (F1 Area: 83.9%). Applying the algorithm, participants with narcolepsy type 1 had 12.8 fewer nap-free days over 28 days and slept 34 minutes more during the day than controls; treatment with oveporexton (TAK-861) increased nap-free days by 6.1-11.9 and reduced daytime sleep by 12-33 minutes versus baseline.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
An actigraphy-based nap detection algorithm reliably identifies nap-based phenotypes that differentiate individuals with narcolepsy type 1 from healthy controls, and demonstrates that an orexin receptor 2-selective agonist reduces napping to normative levels. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
An actigraphy-based nap detection algorithm reliably identifies nap-based phenotypes that differentiate individuals with narcolepsy type 1 from healthy controls, and demonstrates that an orexin receptor 2-selective agonist reduces napping to normative levels.
This conclusion is most relevant to: Participants with narcolepsy type 1 (NT1) and age/sex-matched healthy controls.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸An actigraphy-based algorithm to assess daytime napping in people with narcolepsy type 1. (Sleep, 2026) —
How It Works
The proposed biological pathway:
- ▸Developed nap detection algorithm using wrist-worn actigraphy data from 2237 participants with manually annotated naps
- ▸Validated algorithm for high specificity and accuracy
- ▸Applied algorithm to observational study comparing NT1 patients to controls
- ▸Applied algorithm to randomized clinical trial of orexin receptor 2-selective agonist (oveporexton)
- ▸Result: Algorithm differentiated NT1 from controls and showed treatment reduced napping to near-normal levels
Who Might Benefit
Evidence fit by population:
- ▸Participants with narcolepsy type 1 (NT1) and age/sex-matched healthy controls
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Algorithm developed on general population data (MESA) may not fully capture NT1-specific nap patterns
- ▸Abstract does not report effect sizes or confidence intervals for the differences
- ▸Observational study results may be confounded by lifestyle or medication differences
Frequently Asked Questions
What is the accuracy of the nap detection algorithm?▼
The algorithm has high specificity (Tau B: 93.2%) and accuracy (F1 Area: 83.9%).
How does oveporexton affect napping in narcolepsy type 1?▼
In a randomized clinical trial, oveporexton increased nap-free days by 6.1-11.9 and reduced daytime sleep by 12-33 minutes compared to baseline.
What is the difference in napping between NT1 patients and healthy controls?▼
NT1 patients had 12.8 fewer nap-free days over 28 days and slept 34 minutes more during the day than controls.
What data was used to develop the algorithm?▼
The algorithm was developed using data from the Multi-Ethnic Study of Atherosclerosis, including 2237 participants with 7 days of wrist-worn actigraphy and manually annotated naps.
References
- 1.Torres R, Ghosal R, Naylor M, Gill SK, Pyatkevich Y, Bermingham SL, Buhl DL, Tracey B, Karas M, Onorati F, Zipunnikov V, Volfson D. “An actigraphy-based algorithm to assess daytime napping in people with narcolepsy type 1..” Sleep, 2026. PMID: 42610966 DOI: 10.1093/sleep/zsag219